"Novo has provided and disseminated inaccurate, incomplete and misleading information and failed to disclose internal knowledge and this constitutes price manipulation," the investors' lawyers said in a statement according to Borsen.

According to the plaintiffs, Novo Nordisk has kept its long-term expectations too high for sales at its US insulin-business, Borsen said.